Universe Pharmaceuticals Inc (UPC) Peer Comparison
$4.03
As on 04-Sep-2026 16:00EDT
Market cap
$3 Mln
Revenue (TTM)
$-- Mln
P/E Ratio
--
P/B Ratio
0.1
Div. Yield
0 %
| Universe Pharmaceuticals Inc (UPC) | Theravance Biopharma (TBPH) | Bon Natural Life (BON) | Aptorum Group Limited Class A - ADR | |
|---|---|---|---|---|
Market cap ($ Mln) |
3 | 887 | 12 | 1 |
Revenue ($ Mln) |
18 | 104 | 19 | 1 |
Net Profit ($ Mln) |
-3.67 | 53.81 | -1.99 | -5.68 |
Net Margin (%) |
-- | 51.58 | 15.45 | -591.67 |
RoE (%) |
-7.23 | 18.35 | -3.93 | -49.04 |
Price to Earnings |
-- | 16.42 | -- | -- |
Price-To-Book |
0.05 | 3.06 | 0.17 | 0.28 |
Cashflow ($ Mln)
| Universe Pharmaceuticals Inc (UPC) | Theravance Biopharma (TBPH) | Bon Natural Life (BON) | Aptorum Group Limited Class A - ADR | |
|---|---|---|---|---|
|
Cash From Operating Activities
|
-5.05 | 238.54 | 0.14 | -1.84 |
|
Cash Flow from Investing Activities
|
-0.34 | -105.28 | -10.00 | -- |
|
Cash from Financing Activities
|
9.73 | -3.25 | 15.45 | 4.41 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- |
Ratios
Profitability Ratios
| Universe Pharmaceuticals Inc (UPC) | Theravance Biopharma (TBPH) | Bon Natural Life (BON) | Aptorum Group Limited Class A - ADR | |
|---|---|---|---|---|
|
ROCE (%)
|
-6.62 | 35.44 | -3.29 | -5.34 |
|
ROE (%)
|
-7.23 | 44.85 | -3.93 | -6.16 |
|
ROA (%)
|
-5.35 | 25.22 | -2.71 | -7.83 |
|
EBIT Margin (%)
|
-- | -- | -- | -- |
|
Net Margin (%)
|
-20.56 | 98.54 | -10.68 | -- |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- |
Growth Ratios
| Universe Pharmaceuticals Inc (UPC) | Theravance Biopharma (TBPH) | Bon Natural Life (BON) | Aptorum Group Limited Class A - ADR | |
|---|---|---|---|---|
|
Revenue Growth (%)
|
-0.22 | 0.67 | -0.22 | -- |
|
EBIT Growth (%)
|
-- | -- | -- | -- |
|
Net Profit Growth (%)
|
57.92 | 287.70 | -600.98 | 68.06 |
|
EPS Growth (%)
|
0.27 | 2.74 | -20.16 | 0.98 |
|
Book Value Growth (%)
|
-- | -- | -- | -- |
Valuation Ratios
| Universe Pharmaceuticals Inc (UPC) | Theravance Biopharma (TBPH) | Bon Natural Life (BON) | Aptorum Group Limited Class A - ADR | |
|---|---|---|---|---|
|
Price / Earnings
|
0.00 | 9.37 | -0.33 | -5.72 |
|
Price / Book Value
|
0.00 | 3.35 | 0.01 | 0.34 |
|
Dividend Yield (%)
|
-- | -- | -- | -- |
|
EV/EBITDA
|
8.32 | 5.49 | -116.08 | -4.28 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- |
Solvency Ratios
| Universe Pharmaceuticals Inc (UPC) | Theravance Biopharma (TBPH) | Bon Natural Life (BON) | Aptorum Group Limited Class A - ADR | |
|---|---|---|---|---|
|
Debt to Equity
|
0.16 | 0.25 | 0.21 | 0.15 |
|
Short term debt to equity ratio
|
0.16 | 0.04 | 0.20 | 0.15 |
|
Current Ratio
|
4.07 | 10.93 | 1.74 | 0.78 |
|
Quick Ratio
|
3.90 | -- | 1.01 | -- |
|
Interest Coverage
|
-14.83 | 53.52 | -3.67 | -- |
Operating Efficiency Ratios
| Universe Pharmaceuticals Inc (UPC) | Theravance Biopharma (TBPH) | Bon Natural Life (BON) | Aptorum Group Limited Class A - ADR | |
|---|---|---|---|---|
|
Debtors to sales (%)
|
73.84 | 88.90 | 61.81 | -- |
|
Asset Turnover
|
0.26 | 0.26 | 0.25 | 0.00 |
|
Receivable days
|
266.82 | 278.67 | 228.44 | -- |
|
Inventory Days
|
62.10 | -4,537.51 | 257.00 | -- |
|
Payable days
|
104.04 | 159.28 | 136.67 | -- |
|
Cash Conversion Cycle
|
224.88 | -4,418.12 | 348.77 | -- |